Contribute Try STAT+ Today

Amid rising concern over a lack of antibiotics, a new analysis finds most drug makers are failing to expand their pipelines to sufficiently combat resistance, although more companies are sharing surveillance data on where resistance is occurring and are no longer overselling the medicines.

Overall, the number of antibiotics being developed has increased only marginally in the past two years and just nine of these medicines are considered novel, most of which are being pursued by small and medium-sized companies with fewer resources than global drug makers. And while more clinical-stage antibiotics are supported by plans to ensure better access, most efforts remain patchy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.